Recent Quotes (30 days)

You have no recent quotes
chg | %

Hemostemix Inc  

(Public, CVE:HEM)   Watch this stock  
Find more results for CVE:TIK.P
0.330
+0.010 (3.13%)
May 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.33 - 0.33
52 week 0.32 - 1.10
Open 0.33
Vol / Avg. 5,000.00/16,672.00
Mkt cap 20.27M
P/E     -
Div/yield     -
EPS -0.05
Shares 67.20M
Beta     -
Inst. own     -
Mar 16, 2016
Hemostemix Inc at ROTH Conference
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -465.61% -168.21%
Return on average equity -1080.58% -223.65%
CDP Score - -

Address

1015 4 St SW Suite 730
CALGARY, AB T2R 1J4
Canada
+1-647-9198820 (Phone)

Website links

Description

Hemostemix Inc. is a clinical-stage biotechnology company that develops and commercializes blood-derived cell therapies for medical conditions. The company's lead product ACP-01 is an autologous, blood-derived cell product that is in phase II clinical trial used for the treatment of critical limb ischemia. The Company is also developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs), and neural cell precursors (NCPs). The Company operates a research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona, Israel.